Archived Presentations
Slides available from 2020 Symposium
*Not all presenter slides were approved for release
Mir Alikhan, MD
Northshore University Health System
Rush University Medical Center
The University of Chicago Medicine
Barts Cancer Institute
Tennessee Oncology
Pierluigi Porcu, MD
Jefferson University Hospitals
Jacky Gideon, ANP
The University of Chicago Medicine
Northwestern University
Shunyou Gong, MD, PhD
Northshore University
Pankti Reid, MD
The University of Chicago Medicine
Northshore University Health System
University of Chicago Medicine
Nitin Jain, MD
MD Anderson Cancer Center
Neha Mehta-Shah, MD
Washington University School of Medicine in St. Louis
Erel Joffe, MD, MSc
Memorial Sloan Kettering Cancer Center
University of Utah
Washington University School of Medicine
Girish Venkataraman, MD
The University of Chicago Medicine
Justin Kline, MD
The University of Chicago Medicine
MD Anderson Cancer Center
Ari Melnick, MD
Weill Cornell Medicine
Northshore University Health System
Krishna Komanduri, MD
Northshore University Health System
Jane Winter, MD
Northwestern University
Madhu Menon, MD, PhD
Henry Ford Health System
Slides available from 2020 Symposium
*Not all presenter slides were approved for release
Ultmann Chicago Lymphoma Symposium
The International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that includes five academic centers.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. This year’s meeting will be held virtually on Friday and Saturday and will include a combination of expert presentations, a hematopathology multidisciplinary tumor board discussion, mini symposiums on Indolent lymphoma, Aggressive lymphomas, Primary and Secondary CNS lymphoma, Targeted and Cellular therapies, Imaging, and include a allied healthcare professional session. Additionally, we’ll have a special presentation regarding the impact of COVID-19 on lymphoma treatment.
Virtual symposium components will include:
- LIVE stream session broadcast in real time
- Opportunities to submit questions to presenters during the live broadcast
- Ability to interact with other virtual participants via symposium attendee chat tool
- Access to the virtual exhibit hall for connectivity and information
- CME and MOC credits for physicians and CNE credits for nurses
- Access to download presenter slide decks approved for release
Target Audience
The symposium has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows-in-training, oncology nurses, and allied health professionals committed to the diagnosis and treatment of lymphoma.
Registration Now Open
Lale Kostakoglu, MD, MPH
What is a Metabolic Tumor Volume and How may it be Leveraged in Lymphoma?
Leo Gordon, MD, FACP
Checkpoint Inhibitors in Lymphoma: Rationale Incorporation into Treatment Paradigms
Jennifer Brown, MD, PhD
Optimal Incorporation of New Targeted Agents in the Treatment of CLL
Samir Parekh, MBBS
Application of Precision Medicine in DLBCL
Jaehyuk Choi, MD, PhD
Precision Medicine in T-NHL: Where are We Now?
David Maloney, MD, PhD
Scientific Keynote: Current Applications and Future Innovation in Cell Based Therapy
Ash A. Alizadeh, MD, PhD
Circulating DNA Profiling for Lymphoma
Martin Hutchings, MD, PhD
Should PET Response Adapted Therapy be Utilized in the Therapy of NHL?
Jonathon Cohen, MD, MS
Case Based Series: Frontline Treatment Approaches for MCL
Jason Westin, MD, MS
Case Based Series: How best to Manage Patients with Relapsed MCL
Andreas Engert, MD
Clinical Keynote: Current Status and Future Directions for Newly Diagnosed Hodgkin Lymphoma
Kara Kelly, MD
Should Pediatric AYAs with Hodgkin Lymphoma be Treated Differently than Adult AYAs?
Jorge Castillo, MD
The Assessment and Treatment of Newly Diagnosed Waldenströms Macroglobulinemia
Sonali Smith, MD
How Do I Treat Limited Stage DLBCL?
Daniel J. Landsburg, MD
Novel Therapeutics for the Treatment of Relapsed/Refractory DLBCL
David Weinstock, MD
Translating Scientific Discovery in T-cell Lymphoma: Current and Future States
David Scott, MBChB, PhD, FRACP, FRCPA
Integration of Diagnostic Platforms in DLBCL
Parameswaran Venugopal, MD
DLBCL in 2016: Risk Stratification based on Clinical and Biologic Features
Lynn Wang, MD, PhD, FCAP
Ibrutinib Resistance and Implications for Clinical Practice
Elaine Jaffe, MD
The WHO classification of lymphoma: Historical Perspective and Emerging Issues
Reem Karmali, MD
No Role for Surveillance Imaging in Lymphoma (PRO)
Matt Lunning, DO
No Role for Surveillance Imaging in Lymphoma (CON)
Medhi Hamadani, MD
Beyond Matched Donors: Current Options for Allogeneic Transplantion in Lymphoma
Lindsay Morton, PhD
What Causes Lymphoma: What Should We Tell Our Patients
Youn Kim, MD
Emerging Targets, New Agents, and Improved Therapeutic Strategies in Cutaneous T-cell Lymphoma
Barbara Pro, MD
Peripheral T-Cell Lymphomas: Initial Treatment
Michele Ghielmini, MD, PhD
The Evolution Towards Non-Chemotherapeutic Approaches for Indolent Lymphomas: Pitfalls and Lessons Learned
Ann LaCasce, MD
Early Stage Hodgkin Lymphoma in 2016: Taking Stock of the Evidence
Craig Moskowitz, MD
The Status of Second-Line Thearpy in Hodgkin Lymphoma in the Near Future
Andrew Evens, DO, MSc
Management of Special Populations in Hodgkin Lymphoma
Mary Gospodarowicz, MD
Late Effects of HL Treatment: Are We Doing Any Better?
Owen O’Connor, MD, PhD
Beyond BCR Signaling: New Targets and Therapeutic Approaches in Lymphoma
Eduardo Sotomayor, MD
The Clinical Impact of Mantle Cell Lymphoma Biology
Catherine Bollard, MD
Next Steps in the Development and Application of CAR T-Cell Therapy
Justin Kline, MD
Immunology for the Lymphoma Clinician: How T-Cells and B-Cells Interact
Margaret Shipp, MD
The Translational Path of PD-1 Therapy in Lymphoma
Mitchell Smith, MD, PhD
Chemotherapy Should Be Part of Treatment for High Tumor Burden Follicular Lymphoma (PRO)
Sonali M. Smith, MD
Chemotherapy Should Be Part of Treatment for High Tumor Burden Follicular Lymphoma (CON)
Timothy Fenske, MD
Autologous SCT Should Be a Treatment Option for Relapsed Mantle Cell Lymphoma (PRO)
Patrick Stiff, MD
Autologous SCT Should Be a Treatment Option for Relapsed Mantle Cell Lymphoma (CON)
Nancy Bartlett, MD
Response Adapted Therapy in Hodgkin Lymphoma: How Should It Be Integrated for the Treatment of Patients
Richard R. Furman, MD
Molecular Prognostication of CLL in the Era of Novel Therapeutics
Michael Hallek, MD
Optimal Therapeutic Strategies for Patients with CLL in the Current Era
Jane N. Winter, MD
Prognostication of DLBCL in the Modern Era
Jeremy S. Abramson, MD. MMSc
The Definition and Most Optimal Treatment of High Risk DLBCL
James L. LaBelle, MD, PhD
Targeting Apoptosis in Lymphomas
Leo I. Gordon MD, FACP
Applications of Nanostructures in Lymphoma
George J. Weiner, MD
Implementation of CARTs in Lymphoid Malignancies
Wing C. (John) Chan, MD
Molecular Targets in T-Cell Lymphoma
David L. Porter, MD
CAR-T Cells in Lymphomas: Rationale and Current Progress
Carlo M. Croce, MD
Targeting Micro RNA’s in Lymphoma
Andrew D. Zelenetz, MD, PhD
Patients with Mantle Cell Lymphoma should Receive an Autologous Stem Cell Transplant in First Remission (CON)
Koen van Besien, MD, PhD
Patients with Mantle Cell Lymphoma should Receive an Autologous Stem Cell Transplant in First Remission (PRO)
Michael R. Bishop, MD
Patients with Relapsed DLBCL Should Receive an Autologous not an Allogeneic Stem Cell Transplant in the modern Era
John Kuruvilla, MD
Patients with Relapsed DLBCL Should Receive an Autologous not an Allogeneic Stem Cell Transplant in the modern Era
Bertrand Coiffier, MD, PhD
A Decade after R-CHOP: How should DLBCL be Treated?
Tara Henderson, MD, MPH
Survivorship of Lymphoid Malignancies for the Practitioner
Paul Rubenstein, MD
HIV-Associated Lymphomas in 2014: Spectrum of Disease and Treatment Approach
Sonali M. Smith, MD
MYC-Driven Lymphomas: Diagnostic Considerations and Management Options
Georg Lenz, MD
Dissecting Diffuse Large B-Cell Lymphoma: Why Does It Matter?
Adam Bagg, MD
The Genetics of Lymphoma
Laura Pasqualucci, MD
The Biology of B Cell Transformation
Adam M. Petrich, MD
PI3K/Akt/mTOR Inhibitors in Lymphoma: Predicting Response and Outcome
H. Miles Prince, MD, MBBS
Integrating Novel Therapies into the Management of Cutaneous T Cell Lymphomas
Oliver W. Press, MD, PhD
Emerging Immunotherapies for the Treatment of B Cell Malignancies
James Rubenstein, MD, PhD
Update on CNS Lymphomas: Primary CNS Lymphoma, Intraocular Lymphoma & Leptomeningeal Lymphoma
Bruce D. Cheson, MD
State of the Art: Staging, Restaging and Response Evaluation in Lymphomas
Sonali M. Smith, MD
Challenging Cases in Lymphoma
Andrew M. Evens. DO, MSc
Optimal Front-Line Treatment of Follicular Lymphoma
Timothy S. Fenske, MD
Timing of Hematopoietic Cell Transplantation (HCT) in Follicular Lymphoma
Brian Chiu, PhD
The epidemiology of lymphoma: lessons learned
Susan Bates, MD
Epigenetics of lymphomas: the basics and the next steps
Jonathan Friedberg, MD, MMSc
BCR signaling in lymphoma: relevance and optimal targeting
Myron Czuczman, MD
The microenvironment in lymphoma: is it druggable?
Richard Longnecker, PhD
The biology and pathogenesis of EBV-related lymphomas
Randy D. Gascoyne, MD, FRCPC
Prognostic markers in DLBCL: what is the current standard of care?
Brian Link, MD; Christopher Flowers, MD, MS
Is watch and wait still an appropriate strategy in follicular lymphoma?
Gordon, MD; Scott Smith, MD, PhD; Chadi Nabhan, MD, FACP
PTLD and Burkitt’s lymphoma
Patrick J. Stiff, MD; Koen Van Besien, MD
High risk patients with DLBCL should undergo a stem cell transplant as part of front-line treatment
Volker Diehl, MD, PhD
Hodgkin lymphoma: historical perspective and future
Richard Ambinder, MD, PhD
EBV-related Lymphomas: Prognostic and Therapeutic Implications
Ranjana Advani, MD
Current front-line approach to PTCL
Sonali Smith, MD
Autologous vs. allogeneic stem cell transplant in PTCL
Jim Armitage, MD
Treatment of Follicular Lymphoma: The Role of Transplantation in the Post-Rituximab Era
Koen Van Besien, MD
Standard Therapy for Younger Patients with Mantle-Cell Lymphoma Should Include Stem Cell Transplantation. Pro vs. Con
James Bradner, MD, MSc
Utilizing Chemical Biology to Improve Targeted Therapies in Lymphoma
Elias Campo, MD, PhD
Integrating Molecular Insights into Future Treatments for Mantle Cell Lymphoma
Bouthaina S. Dabaja, MD
Radiotherapy should be standard therapy for primary mediastinal DLBCL Pro vs. Con
Andrew Evens, DO, MS
The Biology and Treatment of Elderly Hodgkin Disease
John Gribben, MD
Importance of Immunity and the Microenvironment in Follicular Lymphoma
Paul A. Hamlin, MD
Evaluation and Treatment of Very Elderly DLBCL
John P. Leonard, MD
Standard Therapy for Younger Patients with Mantle-Cell Lymphoma Should Include Stem Cell Transplantation. Pro vs. Con
Christiane Pott, MD
Minimal Residual Disease in MCL and FL: How, Who, and When?
John M. Pagel, MD, PhD
Application of Immunoconjugates in Non-Hodgkin Lymphoma
Sonali M. Smith, MD
Case Presentation & Discussions
George J. Weiner, MD
Increasing the Efficacy of Monoclonal Antibodies
Wyndham H. Wilson, MD, PhD, NIH, NCI
Radiotherapy should be standard therapy for primary mediastinal DLBCL Pro vs. Con
Shuo Ma, MD, PhD
The Prognosis and Treatment of Elderly CLL
John Anastasi, MD
Grey-Zone Lymphomas
Stephen Ansell, MD, PhD
The Future of Monoclonal Antibodies in Lymphoma: What’s Next?
Steven Bernstein, MD
CNS Prophylaxis: Who and How?
Amy Chadburn, MD
Viral Etiology of Lymphoma
Sandeep S. Dave, MD
MiRNA in NHL
Andrew Evens, DO, MS
Northwestern University
Leo I. Gordon, MD
Purine Analogs in Indolent Lymphoma: Pro Vs. Con
Steve Horwitz, MD
How I Treat: Systemic T-NHL
Brad Kahl, MD
Management of Very High Risk DLBCL: Is There Still a Role for Front-Line Transplant
Peter McLaughlin, MD
Purine Analogs in Indolent Lymphoma: Pro Vs. Con
Ari Melnick, MD
Targeting The Germinal Center: Why and How?
Sonali M. Smith, MD
PI3K/Akt/Mtor Pathway in Lymphoma: Progress Report and Future Outlook
Scott Smith, MD
Management of Very High Risk DLBCL: Is There Still a Role for Front-Line Transplant
Philippe Solal-Celigny, MD, PhD
Keynote Lecture: Prognosis in Follicular Lymphoma in the Modern Era
Joseph Sparano, MD
HIV and NHL in 2010: State of the Art Approach To Front-Line and Relapsed Disease
Koen van Besien, MD
University of Chicago
Denis Weisenberger, MD
T-NHL: Biology and Prognostic Factors
James Cerhan, MD
Genetic Epidemiology: Implications for the Clinical Practitioner
Ken Cohen, MD
NHL microenvironment
Michael Crump, MD
Cure, Late Effects and Prevention in Hodgkin Lymphoma
Andrew Evens, DO, MS
Rational Pathways to Target in Hodgkin lymphoma
Eric Hsi, MD
Biologic predictors and implications on treatment in follicular lymphoma
Neil Kay, MD
Novel approaches and agents for the treatment of relapsed/refractory CLL
Susan O’Brien, MD
Treatment Options for Newly Diagnosed CLL
Michael Pfreundschuh, MD
Perspectives on Front-line DLBCL–Current Status and the Future
Jorge Romaguera, MD
Treatment of mantle cell lymphoma: is upfront aggressive chemotherapy and/or transplant needed?
Mathias Rummel, MD
Pro-Con: Is there a role for ASCT in follicular lymphoma?
Sonali Smith, MD
University of Chicago
Koen van Besien, MD
University of Chicago
Andreas Rosenwald
Biology and Prognosis of High Grade Lymphomas
Sonali Smith
Treatment options for relapsed DLCL
John Sweetenham
Treatment of High Grade Lymphomas
John Leonard
New Monoclonal Antibodies in NHL
John Byrd
CLL: Integration of Biology and Therapeutic Options
Andrew Evens
Challenging Cases: Elderly Hodgkin Disease and Lymphoma with Hepatitis
Julie Vose
Transformed Lymphoma: Definition, Prognosis, and Treatment
Nancy Lee Harris
Pathology and Classification of Follicular Lymphoma: WHO 2008
Thomas Witzig
Sequencing of Therapies in Follicular Lymphoma
Jane Winter
Vaccine Therapy in Lymphoma: Current State of the Art
Izidore Lossos
Gene Array and Diffuse Large B-Cell Lymphoma
Stephanie Gregory
Localized Diffuse Large B-Cell
Leo I. Gordon
Diffuse Large B-Cell Lymphoma
Lauren Abrey
Primary CNS Lymphoma—The Standard of Care
Koen Van Besien
Secondary CNS Lymphoma: Prevention and Treatment
Sonali M. Smith
Challenging Cases: Relapsed T-cell Lymphoma
Finbarr Cotter
Genetics of Mantle Cell Lymphoma: Clinical Implications
Patrick Stiff
Mantle Cell Lymphoma: Role of Stem Cell Transplantation
Martin Dreyling
Mantle Cell Lymphoma—The Next Steps
Lois Travis
Second Cancers Following Hodgkin Lymphoma
Andrew M. Evens
Hodgkin Lymphoma: Advance Stage Disease
Joachim Yahalom
Evolving Role of RT in Hodgkin’s Lymphoma
Madeleine Kraus
Pathology of Hodgkin’s Lymphoma
Volker Diehl
Treatment of Advanced Hodgkin’s Lymphoma
Joseph M. Connors
Nodular Lymphocyte Predominant Hodgkin’s Lymphoma
Andrew Evens
Challenging Cases: Hodgkin Disease with Bulky Disease and Anaplastic T-cell Lymphoma
Steven T. Rosen
Non Cutaneous T-Cell Lymphoma
Koen van Besien
Allogeneic Transplant for Low Grade Lymphoma
Sonali M. Smith
Management of Relapsed Diffuse Large B-Cell Lymphoma
Leo Gordon
Radioimmunotherapy for Low Grade and Aggressive Lymphoma
John Anastasi
Overview on Biology and Classification of Large Cell Lymphoma
Jane N. Winter
Novel Prognostic factors in Large Cell Lymphoma
Sigrid Stroobants
The Use of PET Scanning in Diagnosis and Management of Large Cell Lymphoma
Julie Vose
Monoclonal Antibodies in Aggressive Lymphomas
Wyndham Wilson
The Role of Dose Intensity in Large Cell Lymphoma
Koen van Besien
High Dose Chemotherapy in Large Cell Lymphoma
Emanuele Zucca
Biology and Treatment of Localized MALT Lymphoma
Sonali M. Smith
Management of Disseminated Marginal Zone Lymphoma